WHERE: Tome Bioscience 100 Talcott Avenue Watertown, MA 02472
PROGRAM DETAILS: Trends in Cell and Gene Editing CRISPR, mRNA, and LNP oh my! The field of cell and gene editing is rapidly evolving, spurring innovation across the manufacturing landscape. Come hear about the latest cell and gene editing technologies and their manufacturing strategies.
AGENDA: 4:30 pm Arrival & Networking
Includes food and beverages (two drink tickets will be provided to each attendee)
5:00 pm Introduction by Tome, Panel Discussion, and Q+A 6:00 pm Networking
Matt Barrows, Chief Technology Officer, Tome Biosciences Matt brings over 20 years of senior leadership in chemistry, manufacturing and controls. He was most recently Executive Director, Commercial Manufacturing at Moderna Therapeutics, where he led the manufacturing scale-up of Spikevax, Moderna’s COVID-19 vaccine and Moderna’s Personalized Cancer Vaccine scale-out and production. Prior to that, Matt served as Upstream Manufacturing Lead & Head of Operational Readiness at Alexion Pharmaceuticals and held leadership roles at Genzyme/Sanofi in Manufacturing, Process/Automation Engineering and Consent Decree Remediation. He received his MBA from Northeastern University and BS in Biotechnology from Worcester Polytechnic Institute.
John Finn, PhD, Chief Scientific Office, Tome Biosciences John brings over 20 years of gene therapy experience with a focus on genome editing and delivery technologies. He was most recently Vice President of Discovery Research at Codiak Biosciences, where he led the development of a new class of therapeutics based on engineered exosomes. Prior to Codiak, John was Executive Director of Platform Biology and Liver Discovery at Intellia Therapeutics, where he was responsible for the development of viral and non-viral delivery systems and demonstrated the first in vivo systemic administration of CRISPR-based therapeutics. Previously, John served as Director of Research at Arthrogen, developing novel AAV and exosome-based therapeutics. He serves as an American Society of Gene and Cell Therapy Committee Member for Nanoagents and Synthetic Formulations; Genome Editing; and Metabolic and Inherited Disease. John trained with Pieter Cullis and Ian MacLachlan and received his PhD in Biochemistry and Molecular Biology from the University of British Columbia and BS in Molecular Biology and Genetics from the University of Guelph. He completed post-doctoral programs in Immunology and Vaccine research at McMaster University and Hematology and Gene Therapy with Katherine High at the Children’s Hospital of Philadelphia.
Registration by Thursday, February 8, 2024 Members (Early Bird): $50 Non-Members (Early Bird): $95 Emerging Leaders Members (Early Bird): $20 Student Members: FREE
Registration after Thursday, February 8, 2024 Members: $60 Non-Members: $115 Emerging Leaders Members: $30 Student Members: FREE
**PLEASE NOTE: CANCELLATIONS RECEIVED AFTER FEBRUARY 8 ARE SUBJECT TO BILLING**